Prosecution Insights
Last updated: October 25, 2026
Application No. 18/902,049

COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF

Non-Final OA §103§112
Filed
Sep 30, 2024
Priority
Apr 06, 2022 — CN 2022103540881 +1 more
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shenzhen Antiv Pharma Co. Ltd.
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
2m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
843 granted / 1139 resolved
+14.0% vs TC avg
Strong +31% interview lift
Without
With
+31.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
67 currently pending
Career history
1193
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
16.6%
-23.4% vs TC avg
§102
20.1%
-19.9% vs TC avg
§112
49.8%
+9.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1139 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION RESPONSE TO ELECTION/RESTRICTION Applicant’s election without traverse of group I, drawn to compositions comprising compound in claim 1 in the reply filed on 9/1/2026 is acknowledged. The requirement is still deemed proper and is therefore made FINAL. Claims 13-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 1-12 is contained herein. Priority The application claims priority to Chinese patent application No. 2022103540881, filed on April 6, 2022. However, a certified English version of the foreign priority document was not received. Failure to provide a certified translation may result in no benefit being accorded for the non-English application (i.e., the examiner respectfully requests submission of the appropriate English translated version of the foreign priority document if benefit is sought). See MPEP 213.04. Information Disclosure Statement The examiner has considered the references cited in the information disclosure statement filed of record. Specification Applicant is reminded of the proper content of an Abstract of the Disclosure, see MPEP 608.01(b). In chemical patent abstracts for compounds or compositions, the general nature of the compound or composition should be given as well as its use, e.g., "The compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics." Exemplification of a species could be illustrative of members of the class. For processes, the type reaction, reagents and process conditions should be stated, generally illustrated by a single example unless variations are necessary. It is recommended that the structure of claim 1 be inserted into the abstract to accurately illustrate the claimed invention. Claim Objections Claims 5-10 are objected to because of the following informality: The language “according claim 2” should more appropriately read “according to claim 2”. Thus the claim and claims dependent on it are objected to. Correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2-12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. In the instant claim 2, the scope of “other auxiliary materials” is neither defined in the claim itself or the specification as filed. What types of “materials” fall within the scope of this language? Thus the claim and claims dependent on it which do not rectify the issue are considered indefinite. In claim 3 the phrase "preferably" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claim 8 recites the language “can be 1.5%..”. What does Applicant intend by the language “can be”? It could suggest “is”, “optionally”, or something else. Thus the scope is indefinite. See In re Zletz, 13 USPQ2d 1320, 1322, “An essential purpose of patent examination is to fashion claims that are precise, clear, correct and unambiguous.” Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), fourth paragraph: Subject to the [fifth paragraph of 35 U.S.C. 112 (pre-AIA )], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 4 and 11-12 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The aforementioned claims do not further limit claim 2 with respect to “external lubricant” since the latter was not recited previously. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent Publication 2002/0081462- mentioned in IDS. US 2002/0081462 teach the compound of claim 1 at page 15, right column. The document further teaches that the compounds (including the species at page 15) may be formulated into compositions that include the recited binders, lubricants, etc. (see [0169]). Excipients such as magnesium stearate and other claimed embodiments are taught at [0175]-[0177] in addition to ranges of active compound to excipient at [0182]. Thus, based on the teachings of the document one skilled in the art would have readily arrived at the claimed compositions. Limitations citing specified amounts of carrier, active compound, etc. would be considered routine optimization by one skilled in the art. Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN E MCDOWELL/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Sep 30, 2024
Application Filed
Oct 13, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12753196
ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
3y 6m to grant Granted Oct 06, 2026
Patent 12753167
INTERMEDIATE OF BILIVERDIN, AND PREPARATION METHOD AND USE THEREOF
3y 3m to grant Granted Oct 06, 2026
Patent 12747223
N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES
3y 3m to grant Granted Sep 29, 2026
Patent 12741943
Sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate, its preparation and use
4y 0m to grant Granted Sep 22, 2026
Patent 12741959
Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host Disease
2y 6m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+31.0%)
2y 2m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1139 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month